Reports
Sale
Synovial Sarcoma Market Size, Share, Analysis, Forecast: By Diagnosis: Imaging, Biopsy, Others; By Type: ACXT-3102, AL-3818, Axitinib, CMB-305, CUE-102, Others; By Treatment: Surgery, Anti-Angiogenesis Drugs, Radiation Therapy, Chemotherapy; By Distribution Channel; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Synovial Sarcoma Market Outlook
The synovial sarcoma market size is expected to grow at a CAGR of 4% during the forecast period of 2024-2032, driven by the increasing incidence of the disease along with rising technical advances to offer targeted therapies to patients.
Synovial Sarcoma Market Overview
Synovial sarcoma, also known as soft tissue sarcoma, is a rare cancer occurring in the connective tissues of the body. It usually affects the arms, legs, and belly. Symptoms include a painless lump in the hip, knee, ankle to shoulder. A sudden sharp pain along with swelling may also persist in patients. Synovial sarcoma is mostly slow growing and can be diagnosed via imaging tests, or biopsy.
In 2023, around 13,400 new soft tissue sarcomas are expected to be diagnosed in the United States. While 5,140 deaths (2,720 males and 2,420 females) are associated with the condition. It is more prevalent in adolescents and adults younger than 30 years of age, making it the third most commonly occurring in young adults and adolescents. The survival rate is approximately 50-60% at 5 years and 40-50% at 10 years. The ongoing advancements in oncology domain and monoclonal antibodies development are expected to improve the survival rates significantly.
Development in CAR T-cell Therapies for Personalized Treatment
To beat the rising mortalities associated with the condition, the synovial sarcoma market growth has been quite significant in recent years. In December 2023, Adaptimmune Therapeutics plc , a cancer therapy leader announced the submission of its Biologics License Application (BLA) to the FDA for afami-cel. Afami-cell is an investigational T-cell therapy intended to target melanoma-associated antigen (MAGE)-A4 and mesothelin, which has been supported by the positive data from SPEARHEAD-1 trial.
Advancements in Immunotherapy to Meet Synovial Sarcoma Market Demand
Immunotherapy has been a key area of investigation amongst researchers, owing to its ability to offer customized and effective treatment to patients. An October 2023 study published in Clinical Cancer Research revealed that immunotherapy with TB-1301 that targets NY-ESO-1-positive tumor cells showcased promising outcomes against recurrent synovial sarcoma. As per researchers, the efficacy and objective response rate was significantly better against pazopanib (Votrient) and other immunotherapy regimens. This indicates that the upcoming progressions in biotechnology and gene therapy are expected to build improved therapies.
Increased Research Activities to Identify Disease Prognosis
In July 2023, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) researchers, upon the molecular analysis of the tumor identified that a BRAF V600E mutation was responsible for progression of relapsed disease. Such initiatives aimed at identifying the root cause of tumor progression at genetic level are expected to help the scientists come up with better therapeutic alternatives and lead to an increased synovial sarcoma market share in coming years.
Improvement in Existing Methods of Therapy
Over the years, medications such as doxorubicin, halaven and imatinib, along with radiotherapy have been used to shrink tumor size. This also helps in ensuring the accuracy in surgery. There have been high investments and research in developing new and effective medications, which are anticipated to increase the synovial sarcoma market size in the forecast period. Currently, Trabectedin, also known as Ecteinascidin-743 (ET-743) is administered to patients. TKI inhibitors such as Pazopanib are also considered effective.
Synovial Sarcoma Market Segmentation
Market Breakup by Diagnosis
- Imaging
- Biopsy
- Others
Market Breakup by Type
- ACXT-3102
- AL-3818
- Axitinib
- CMB-305
- CUE-102
- Others
Market Breakup by Treatment
- Surgery
- Anti-Angiogenesis Drugs
- Radiation Therapy
- Chemotherapy
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Others
Market Breakup by End User
- Hospital
- Clinics
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Synovial Sarcoma Market Regional Analysis
Europe, especially with a significant amount of geriatric population, holds high market value. The existence of several research and academic institutions plays a pivotal role in boosting market growth by offering novel treatments that showcase improved efficacy and reduced side effects. The increasing progression of clinical trials also impacts the market positively. The United States is anticipated to lead the synovial sarcoma market share owing to its well-equipped and technically advanced healthcare infrastructure. Several pharmaceutical companies are collaborating with advanced start-ups to leverage the latest techniques and devise quality treatment options to address the unmet needs of patients suffering from the disease.
The Asia Pacific, led by Japan is projected to experience a significant upswing in the synovial sarcoma market value. The growth can be credited to increasing healthcare investment in the region. Governments and organisations are also working on raising awareness via campaigns and programs to help the masses assess the early signs of the condition.
Synovial Sarcoma Market: Competitor Landscape
In November 2023, a clinical stage biotechnology firm Intensity Therapeutics, Inc . revealed that their lead proprietary investigational product candidate called INT230-6, alone or in combination with ipilimumab, was safe, tolerable, and effective in treating patients with relapsed, refractory, and metastatic sarcomas. The company using latest technologies such as the DfuseRxâ„ technology platform. This also indicates the trend of prominent companies deploying novel technologies to develop effective solutions for patients.
The key features of the synovial sarcoma market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- F. Hoffmann-La Roche Ltd
- Bayer AG
- Epizyme
- Bionpharma Cue Biopharma
- Eli Lilly and Company
- Adaptimmune Therapeutics Plc
- Advenchen Laboratories LLC
- EpiZyme Inc
- Merck & Co
- Immunocore Ltd
- Johnson & Johnson Private Limited
- Karyopharm Therapeutics Inc
- Novartis AG
- Pfizer Inc
- Takara Bio Inc
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Diagnosis |
|
| Breakup by Type |
|
| Breakup by Treatment |
|
| Breakup by Distribution Channel |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Synovial sarcoma Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Drug
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Synovial sarcoma Epidemiology Analysis – Seven Major Markets
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Synovial Sarcoma Forecast (2017-2032)
5.3 EU-4 and United Kingdom Synovial Sarcoma Epidemiology Forecast (2017-2032)
5.3.1 Germany Synovial sarcoma Epidemiology Forecast (2017-2032)
5.3.2 France Synovial sarcoma Epidemiology Forecast (2017-2032)
5.3.3 Italy Synovial sarcoma Epidemiology Forecast (2017-2032)
5.3.4 Spain Synovial sarcoma Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Synovial Sarcoma Epidemiology Forecast (2017-2032)
5.4 Japan Synovial sarcoma Epidemiology Forecast (2017-2032)
6 Synovial Sarcoma Market Overview – Seven Major Markets
6.1 Synovial Sarcoma Market Historical Value (2017-2023)
6.2 Synovial Sarcoma Market Forecast Value (2024-2032)
7 Synovial Sarcoma Market Landscape – Seven Major Markets
7.1 Synovial Sarcoma: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Synovial Sarcoma Product Landscape
7.2.1 Analysis by Diagnosis
7.2.2 Analysis by Type
8 Synovial Sarcoma Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Synovial Sarcoma Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Synovial Sarcoma Market Segmentation – Seven Major Markets
11.1 Synovial Sarcoma Market by Diagnosis
11.1.1 Market Overview
11.1.2 Imaging
11.1.3 Biopsy
11.1.4 Others
11.2 Synovial Sarcoma Market by Type
11.2.1 Market Overview
11.2.2 ACXT-3102
11.2.3 AL-3818
11.2.4 Axitinib
11.2.5 CMB-305
11.2.6 CUE-102
11.2.7 Others
11.3 Synovial Sarcoma Market by Treatment
11.3.1 Market Overview
11.3.2 Surgery
11.3.3 Anti-Angiogenesis Drugs
11.3.4 Radiation Therapy
11.3.5 Chemotherapy
11.4 Synovial Sarcoma Market by Distribution Channel
11.4.1 Market Overview
11.4.2 Hospital Pharmacy
11.4.3 Retail Pharmacy
11.4.4 Others
11.5 Synovial Sarcoma Market by End User
11.5.1 Market Overview
11.5.2 Hospital
11.5.3 Clinics
11.6 Synovial Sarcoma Market by Region
11.6.1 Market Overview
11.6.2 United States
11.6.3 EU-4 and the United Kingdom
11.6.3.1 Germany
11.6.3.2 France
11.6.3.3 Italy
11.6.3.4 Spain
11.6.3.5 United Kingdom
11.6.4 Japan
12 United States Synovial Sarcoma Market
12.1 Synovial Sarcoma Market Historical Value (2017-2023)
12.2 Synovial Sarcoma Market Forecast Value (2024-2032)
12.3 Synovial Sarcoma Market by Diagnosis
12.4 Synovial Sarcoma Market by Type
13 EU-4 and United Kingdom Synovial Sarcoma Market
13.1 Synovial Sarcoma Market Historical Value (2017-2023)
13.2 Synovial Sarcoma Market Forecast Value (2024-2032)
13.3 Germany Synovial Sarcoma Market Overview
13.3.1 Synovial Sarcoma Market by Diagnosis
13.3.2 Synovial Sarcoma Market by Type
13.4 France Synovial Sarcoma Market Overview
13.4.1 Synovial Sarcoma Market by Diagnosis
13.4.2 Synovial Sarcoma Market by Type
13.5 Italy Synovial Sarcoma Market Overview
13.5.1 Synovial Sarcoma Market by Diagnosis
13.5.2 Synovial Sarcoma Market by Type
13.6 Spain Synovial Sarcoma Market Overview
13.6.1 Synovial Sarcoma Market by Diagnosis
13.6.2 Synovial Sarcoma Market by Type
13.7 United Kingdom Synovial Sarcoma Market Overview
13.7.1 Synovial Sarcoma Market by Diagnosis
13.7.2 Synovial Sarcoma Market by Type
14 Japan Synovial Sarcoma Market
14.1 Synovial Sarcoma Market Historical Value (2017-2023)
14.2 Synovial Sarcoma Market Forecast Value (2024-2032)
14.3 Synovial Sarcoma Market by Diagnosis
14.4 Synovial Sarcoma Market by Type
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnerships and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 F. Hoffmann-La Roche Ltd
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Bayer AG
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Epizyme
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 Bionpharma Cue Biopharma
21.4.1 Product Portfolio
21.4.2 Demographic Reach and Achievements
21.4.3 Mergers and Acquisitions
21.4.4 Certifications
21.5 Eli Lilly and Company
21.5.1 Product Portfolio
21.5.2 Demographic Reach and Achievements
21.5.3 Mergers and Acquisitions
21.5.4 Certifications
21.6 Adaptimmune Therapeutics Plc
21.6.1 Product Portfolio
21.6.2 Demographic Reach and Achievements
21.6.3 Mergers and Acquisitions
21.6.4 Certifications
21.7 Advenchen Laboratories LLC
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 EpiZyme Inc
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Merck & Co
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Immunocore Ltd
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Johnson & Johnson Private Limited
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Karyopharm Therapeutics Inc
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 Novartis AG
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
21.14 Pfizer Inc
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
21.15 Takara Bio Inc
21.15.1 Financial Analysis
21.15.2 Product Portfolio
21.15.3 Demographic Reach and Achievements
21.15.4 Mergers and Acquisitions
21.15.5 Certifications
22 Synovial Sarcoma Market- Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 4% during the forecast period of 2024-2032, driven by the increasing incidence of the disease, along with increasing technical advances to provide targeted therapies to patients.
The market demand is driven by increasing awareness of the disease among the public which has fuelled the frequency of clinical trials and drug approvals in recent times.
The current market trend is majorly around growing developments in gene therapy and combination therapies. A Clinical Cancer Research study published in October 2023 revealed that TB-1301 targets NY-ESO-1-positive tumor cells demonstrated positive results against pazopanib (Votrient) and other immunotherapy regimens.
Based on product types, the market is divided into ACXT-3102, AL-3818, Axitinib, CMB-305, and CUE-102, among others.
Major end users include hospitals and clinics.
Surgery, anti-angiogenesis, drugs, radiation therapy, and chemotherapy are common treatments available in the market.
Imaging, biopsy and others are common types of diagnosis.
The major regions of the market include the United States, Japan, EU-4 which is segmented into Germany, France, Italy, Spain, and the United Kingdom.
Key players involved in the market are F. Hoffmann-La Roche Ltd., Bayer AG, Epizyme, Bionpharma Cue Biopharma, Adaptimmune Therapeutics Plc, Advenchen Laboratories LLC, EpiZyme Inc., Merck & Co., Immunocore Ltd., Johnson & Johnson Private Limited., Karyopharm Therapeutics Inc., Novartis AG, Pfizer Inc., Takara Bio Inc., and Eli Lilly and Company.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER